So far, there is no report regarding association between DNMT3A polymorphisms and the outcome of AML patients, although polymorphisms in some genes are shown to play vital roles in initiation and development of hematologic malignancies [41–44]. This evidence concerns the gene DNMT3A and acute myeloid leukemia.